Skip to Content

Diane Liu, M.S.

Principal Statistical Analyst

Degrees

  • M.Stat. in Biostatistics,  University of Utah, Salt Lake City,  Utah
  • M.S. in Anatomy, University of Utah, Salt Lake City, Utah
  • M.S. in Neurophysiology, University of Science and Technology of China

Areas of Interest

  • Clinical trial design/sample size calculation
  • Statistical model building and validation including survival analysis and longitudinal data analysis
  • Statistical programming in SAS and S-Plus
  • Database management for clinical research

Publications

Research / Methodology

Thall PF, Liu D, Berrak SG, Wolff J. Defining and ranking effects of individual agents based on survival times of cancer patients treated with combination chemotherapies. Statistics in Medicine 2011; 30(15): 1777-1794.   

Lee JJ, Lin HY, Liu DD, Kong M. Applying Emax model and interaction index for assessing drug interaction in combination studies. Frontiers in Bioscience (Elite Edition) 2010; E2: 582-601.

Biswas S, Liu DD, Lee JJ, Berry DA, Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clinical Trials 2009; 6(3): 205-216.

Kajiwara Y, Panchabhai S, Liu DD, Kong M, Lee JJ, Levin VA. Melding a new 3-dimensional agarose colony assay with the E(max) model to determine the effects of drug combinations on cancer cells. Technology in Cancer Research and Treatment 2009; 8(2): 163-176.

Lee JJ, Liu DD. A predictive probability design for phase II cancer clinical trials. Clinical Trials 2009; 5: 93-106.

Biomarkers

Xu J, Wan M, He Q, Bassett RL Jr, Fu X, Chen AC, Shi F, Creighton CJ, Schiff R, Huo L, Liu D. SGK3 is associated with estrogen receptor expression in breast cancer. Breast Cancer Research and Treatment 2012; 134(2): 531-41.

Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu JM, Huo L, Labaff AM, Liu D, Huang TH, Lai CC, Tsai FJ, Chang WC, Chen CH, Wu TT, Buttar NS, Wang KK, Wu Y, Wang H, Ajani J, Hung MC. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 2012; 21(3): 374-387.

Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BK.  Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 2011; 118(4): 908-913. 

William WN, Kim JS, Liu DD, Solis L, Behrens C, Lee JJ, Lippman SM, Kim ES, Hong WK, Wistuba II, Lee HY. The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival.  Annals of Oncology 2012; 23(1): 78-85. 

Tsuta K, Raso MG, Kalhor N, Liu D, Wistuba II, Moran CA.  Sox10-positive sustentacular cells in neuroendocrine carcinoma of the lung.  Histopathology 2011; 58(2): 276-285.

Tsuta K, Liu D, Kalhor N, Wistuba II, Moran CA. Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas. American Journal of Clinical Pathology 2011; 136(2): 252-259.

Tang X, Kadara H, Behrens C, Liu D, Xiao Y, Rice DC, Gazdar AF, Fujimoto J, Moran C, Varella-Garcia M, Lee JJ, Hong WK, Wistuba II. Abnormalities of theTITF-1 lineage-specific oncogene in NSCLC: Implications in lung cancer pathogenesis and prognosis. Clinical Cancer Research 2011; 17(8): 2434-2443.

Roybal JD, Zang Y, Ahn YH, Yang Y, Gibbons DL, Baird BN, Alvarez C, Thilaganathan N, Liu DD, Saintigny P, Heymach JV, Creighton CJ, Kurie JM. miR-200 inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Molecular Cancer Research 2011; 9(1): 25-35.

Kadara H, Behrens C, Yuan P, Solis LM, Liu D, Gu X, Minna JD, Lee JJ, Kim ES, Hong WK, Wistuba II, Lotan R. A five-gene and corresponding protein signature for stage-I lung adenocarcinomas prognosis. Clinical Cancer Research 2011; 17(6): 1490-1501.

Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene 2010; 29(18): 2616-2627.

Kim ES, Hong WK, Lee JJ, Mao L, Morice RC, Liu DD, Jimenez CA, Eapen GA, Lotan R, Tang X, Newman RA, Wistuba II, Kurie JM. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prevention Research 2010; 3(2): 148-159.

Prudkin L, Liu DD, Ozburn NC, Sun M, Behrens C, Tang X, Brown KC, Bekele BN, Moran C, Wistuba II. Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Modern Pathology 2009; 22(5): 668-678.

Papadimitrakopoulou V, Izzo JG, Liu DD, Meyers J, Ceron TL, Lewin J, Wiliam WN, Atwell A, Lee JJ, Gillenwater A, El-Naggar A, Wu Xifeng, Lippman SM, Hittelman WN, Hong WK. Cyclin D1 alterations and cancer development in a chemoprevention trial in laryngeal premalignancy. Cancer Prevention Research 2009; 2(1): 14-21.

Gibbons DL, Lin W, Creighton CJ, Zheng S, Berel D, Yang Y, Raso MG, Liu DD, Wistuba II, Lozano G, Kurie JM. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One 2009; 4(4): e5401. 

Yang Y, Wislez M, Fujimoto N, Prudkin L, Izzo JG, Uno F, Ji L, Hanna AE, Langley RR, Liu D, Johnson FM, Wistuba I, Kurie JM. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Molecular Cancer Therapy 2009; 7(4): 952-960.

Prudkin L, Behrens C, Liu DD, Zhou X, Ozburn NC, Bekele BN, Minna JD, Moran C, Roth JA, Ji L, Wistuba II. Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clinical Cancer Research 2008; 14: 41-47.

Bhutani M, Pathak AK, Fan YH, Liu DD, Lee JJ, Tang H, Kurie JM, Morice RC, Kim ES, Hong WK, Mao L.Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prevention Research 2008; 1: 39-44.

Seo HS, Liu D, Bekele BN, Kim SW, Hong JS, Kim MK, Hong WK, Wistuba I, Koo JS. Cyclic AMP response element-binding protein overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung cancer. Cancer Research 2008; 68(15): 6065-6073.

Khatlani TS, Wislez M, Sun M, Srinivas H, Iwanaga K, Ma L, Hanna AE, Liu D, Girard L, Kim YH, Pollack JR, Minna JD, Wistuba II, Kurie JM. c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene 2007; 26(18): 2658-2666.

Hittelman WN, Liu DD, Kurie JM, Lotan R, Lee JS, Khuri F, Ibarguen H, Morice RC, Walsh G, Roth JA, Minna J, Ro JY, Broxson A, Hong WK, Lee JJ. Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. Journal of the National Cancer Institute 2007; 99: 1603-1612.

Temam S, Kawagushi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ, Mao L. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. Journal of Clinical Oncology 2007; 25(16): 2164-2170.

Khatlani TS, Wislez M, Sun M, Srinivas H, Iwanaga K, Ma L, Hanna AE, Liu D, Girard L, Kim YH, Pollack JR, Minna JD, Wistuba II, Kurie JM. c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene 2007; 26(18): 2658-2666.

Massarelli E, Varella-Garcia M, Tang XM, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancer. Clinical Cancer Research 2007; 13: 2890-2896.

Tang XM, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, Hong WK, Aggarwal BB, Wistuba II. Nuclear factor-kappaB (NF-kappaB) is frequently activated in lung cancer and preneoplastic lesions. Cancer 2006; 107(11): 2637-2646.

Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ, Mao L. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006; 107(3): 563-569.

Wang J, Walsh G, Liu DD, Lee JJ, Mao L. Expression of DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non–small cell lung cancer. Cancer Research 2006; 66: 8361-8366.

Papadimitrakopoulou VA, Brown EN, Liu DD, El-Naggar AK, Lee JJ, Hong WK, Lee HY. The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Letters 2006; 239(1): 136-143.

Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN, Papadimitrakopoulou VA. Akt activation correlates with adverse outcome in tongue cancer. Cancer 2005; 104(11): 2430-2436.

Han JY, Liu DD, Lee JJ, Kurie J, Lotan R, Hong WK, Lee HY. 9-cis-retinoic acid treatment increases serum concentrations of alpha-tocopherol in former smokers. Clinical Cancer Research 2005; 11(6): 2305-2311.

Lee HY, Chang YS, Han JY, Liu DD, Lee JJ, Lotan R, Spitz MR, Hong WK. Effects of 9-cis-retinoic acid on the insulin-like growth factor axis in former smokers. Journal of Clinical Oncology 2005; 23(19): 4439-4449.

Massarelli E, Brown E, Tran NK, Liu DD, Izzo JG, Lee JJ, El-Naggar AK, Hong WK, Papadimitrakopoulou VA. Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer 2005; 103(5): 952-959.

Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan YH, Hong WK, Mao L. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clinical Cancer Research 2004; 10(18 Pt 1): 6119-6125.

Tai SK, Lee JI, Ang KK, El-Naggar, Hassan KA, Liu D, Lee JJ, Ren H, Hong WK, Mao L. Loss of Fhit expression in head and neck squamous cell carcinoma and its potential clinical implication. Clinical Cancer Research 2004; 10(16): 5554-5557.

Soria JC, Moon C, Kemp BL, Liu DD, Feng L, Tang X, Chang YS, Mao L, Khuri FR. Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. Clinical Cancer Research 2003; 9(5): 1785-1791.

Izzo JG, Papadimitrakopoulou VA, Liu DD, den Hollander PL, Babenko IM, Keck J, El-Naggar AK, Shin DM, Lee JJ, Hong WK, Hittelman WN. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. Journal of the National Cancer Institute 2003; 95(3): 198-205.

Kurie JM, Lotan R, Lee JJ, Lee JS, Morice RC, Liu DD, Xu XC, Khuri FR, Ro JY, Hittelman WN, Walsh GL, Roth JA, Minna JD, Hong WK. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. Journal of the National Cancer Institute 2003; 95(3): 206-214.

Soria JC, Xu X, Liu DD, Lee JJ, Kurie J, Morice RC, Khuri F, Mao L, Hong WK, Lotan R. Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. Journal of the National Cancer Institute 2003; 95(2): 165-168.

Papadimitrakopoulou VA, Liu DD, Mao L, Shin DM, El-Naggar A, Ibarguen H, Lee JJ, Hong WK, Hittelman WN. Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions. Cancer Epidemiology, Biomarkers, Prevention 2002; 11(12): 1605-1610.

Wang L, Soria JC, Kemp BL, Liu DD, Mao L, Khurie FR. hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clinical Cancer Research 2002; 8(9): 2883-2889.

Hassan KA, Ang KK, El-Naggar AK, Story MD, Lee JI, Liu D, Hong WK, Mao L. Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Research 2002; 62(22): 6414-6417.

Chang YS, Kong G, Sun S, Liu D, El-Naggar AK, Khuri FR, Hong WK, Lee HY. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clinical Cancer Research 2002; 8(12): 3796-3802.

Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, Lee HY. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clinical Cancer Research 2002; 8(12): 3669-3675.

Albitar M, Manshouri T, Shen Y, Liu D, Beran M, Kantarjian HM, Rogers A, Jilani I, Lin CW, Pierce S, Freieich E, Estey EH. Myelodysplastic syndrome is not merely “preleukemia.” Blood 2002; 100(3): 791-798.

Jeha S, Smith FO, Estey E, Shen Y, Liu D, Manshouri T, Albitar M. Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels. Leukemia Research 2002; 26(4): 399-402.

Soria JC, Rodriguez M, Liu DD, Lee JJ, Hong WK, Mao L. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Research 2002; 62(2): 351-355.

Lee JI, Soria JC, Hassan KA, El-Naggar AK, Tang X, Liu DD, Hong WK, Mao L. Loss of PTEN expression as a prognostic marker for tongue cancer. Archives of Otolaryngology, Head and Neck Surgery 2001; 127(12): 1441-1445.

Papadimitrakopoulou VA, Izzo J, Mao L, Keck J, Hamilton D, Shin DM, El-Naggar A, den Hollander P, Liu D, Hittelman WN, Hong WK. Cyclin D1 and p16 alteration in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clinical Cancer Research 2001; 7(10): 3127-3134.

Soria JC, Moon C, Wang L, Hittelman WN, Jang SJ, Sun SY, Lee JJ, Liu D, Kurie JM, Morice RC, Lee JS, Hong WK, Mao L. Effects of N-(4-hydroxyphenyl) retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. Journal of the National Cancer Institute 2001; 93(16): 1257-1263.

Hassan KA, El-Naggar AK, Soria JC, Liu D, Hong WK, Mao L. Clinical significance of cyclin B1 protein expression in squamous cell carcinoma of the tongue. Clinical Cancer Research 2001; 7(8): 2458-2462.

Lee JJ, Liu D, Lee JS, Kurie JM, Khuri FR, Ibarguen H, Morice RC, Walsh G, Ro JY, Broxson A, Hong WK, Hittelman WN. Long-term impact of smoking on lung epithelial proliferation in current and former smokers. Journal of the National Cancer Institute 2001; 93(14): 1081-1088.

Lee JI, Soria JC, Hassan K, Liu D, Tang X, El-Naggar A, Hong WK, Mao L. Loss of Fhit expression is a predictor of poor outcome in tongue cancer. Cancer Research 2001; 61(3): 837-841.

Kurie JM, Lee JS, Khuri FR, Mao L, Morice RC, Lee JJ, Walsh GL, Broxson A, Lippman SM, Ro JY, Kemp BL, Liu D, Fritsche HA, Xu X, Lotan R, Hong WK. N-(4-hydroxyphenyl) retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clinical Cancer Research 2000; 6(8): 2973-2979.

Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, Mao L. Hypermethylation of the death associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. Journal of the National Cancer Institute 2000; 92(18): 1511-1516.

Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, Mao L. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Research 2000; 60(15): 4000-4004.

Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, Liu D, Kemp B, Lee JJ, Hong WK, Fidler IJ. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clinical Cancer Research 2000; 6(3): 790-797.

Zhou X, Kemp BL, Khuri FR, Liu D, Lee JJ, Wu W, Hong WK, Mao L. Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer. Clinical Cancer Research 2000; 6(2): 559-565.

Tseng JE, Rodriguez M, Ro J, Liu D, Hong WK, Mao L. Gender difference in p53 mutational status in small cell lung cancer. Cancer Research 1999; 59(22): 5666-5670.

Tseng JE, Kemp BL, Khuri FR, Kurie JM, Lee JS, Zhou X, Liu D, Hong WK, Mao L. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Research 1999; 59(19): 4798–4803.

Clinical

Albert JM, Liu DD, Shen Y, Pan IW, Shih YC, Hoffman KE, Buchholz TA, Giordano SH, Smith BD. Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. Journal of Clinical Oncology 2012; 30(23): 2837-2843.

Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, Lippman SM, Hong WK, Wistuba II, Lee HY. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer 2012; 118(9): 2454-2465. 

Tsuta K, Raso MG, Kalhor N, Liu DD, Wistuba II, Moran CA, Histologic features of low- and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung. Lung Cancer 2011; 71(1):34-41.

Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 mutation carriers: A single institution experience. Journal of Clinical Oncology 2011; 29(28): 3739-3746.

Berrak SG, Liu DD, Wrede B, Wolff JE.  Which therapy works better in choroid plexus carcinomas? Journal of Neuro-Oncology 2011; 103(1): 155-162.

Wolff JE, Rytting M, Vats T, Ater J, Mahajan A, Woo S, Ketonen L, Kuttesch J, Liu D, Thall P, Chang EL. Induction treatment for diffuse intrinsic pontine glioma, experience of M.D. Anderson Cancer Center. Anticancer Research 2011; 31(6): 2265-2270. 

Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Research and Treatment 2011; 130(1): 145-153. 

William WN Jr, Kies MS, Fossella FV, Liu DD, Gladish G, Tse WH, Lee JJ, Hong WK, Lippman SM, Kim ES. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer 2010; 116(10): 2401-2408.

Kim ES, Hong WK, Lee JJ, Mao L, Morice RC, Liu DD, Jimenez CA, Eapen GA, Lotan R, Tang X, Newman RA, Wistuba II, and Kurie JM.  Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prevention Research 2010; 3: 148-159.

Tsao AS, Liu D, Martin J, Tang X, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prevention Research 2009; 2: 931-941.

Kim ES, Mauer AM, William WN Jr, Tran HT, Liu D, Lee JJ, Windt P, Hong WK, Vokes EE, Herbst RS. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 2009; 115(8): 1713-1722.

Bhutani M, Pathak AK, Fan YH, Liu DD, Lee JJ, Tang H, Kurie JM, Morice RC, Kim ES, Hong WK, Mao L.  Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prevention Research 2008; 1(1): 39-44.

Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 2006; 106(11): 2428-2436.

Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. Journal of Clinical Oncology 2005; 23(11): 2544-2555.

Massarelli E, Andre F, Liu DD, Lee JJ, Wolf M, Fandi A, Ochs J, Le Chevalier T, Fossella F, Herbst RS. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003; 39(1): 55-61.

Papadimitrakopoulou VA, Ginsberg LE, Garden AS, Kies MS, Glisson BS, Diaz EM Jr, Clayman G, Morrison WH, Liu DD, Blumenschein G Jr, Lippman SM, Schommer D, Gillenwater A, Goepfert H, Hong WK. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer 2003; 98(10): 2214-2223.

Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G Jr, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer 2002; 95(2): 340-353.

Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. Journal of Clinical Oncology 2002; 20(2): 364-370.

Kim ES, Lu C, Khuri FR, Tonda M, Glisson BS, Liu D, Jung M, Hong WK, Herbst RS. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 2001; 34(3): 427-432.

Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M, Liu D, Glisson BS, Ginsberg L, Papadimitrakopoulou V, Myers J, Morrison W, Gillenwater A, Ang KK, Lippman SM, Goepfert H, Hong WK. Combined interferon-alfa, 13-cis-retinoic acid and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. Journal of Clinical Oncology 2001; 19(12): 3010-3017.

 

Updated March 7, 2013


© 2014 The University of Texas MD Anderson Cancer Center